Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1226

Monoclonal Antibodies to Native Murine CCR9

Inventors: James Campbell, Marc-Andrae Wurbel

Invention Types: Research Tool

Research Areas: Gastrointestinal/Nutrition, Immunology

Keywords: Antibody, Reagent

For More Information Contact:  Caron, Connie

 

Invention Description:

The CCR9 receptor is a G protein-coupled seven-transmembrane receptor expressed on thymocytes and other intestine-homing cells. It has been proposed that CCR9 is necessary to allow lymphocytes access to intestinal sites. Drugs that block CCR9 from binding with its chemokine ligand CCL25 or TECK may be useful treatments for inflammatory bowel diseases. Six monoclonal antibodies that detect murine CCR9 have been generated.

CCR9-deficient mice were immunized with murine thymocytes expressing native CCR9. B cells from the immunized mice were fused to a murine myeloma to produce six hybridoma clones. No cross-reactivity with human and rat CCR9 has been identified. The antibodies have been tested for use in flow cytometry and immunohistochemistry.

Applications:

Assay
Drug Screening
Research Tool

Competitive Advantages:

Since these anti-mouse antibodies are of mouse origin, they will be tolerated upon injection into mice and may be helpful in animal models to assess the usefulness of potential drugs that block CCR9 function.

Business Opportunity:

Non-Exclusive License

Key Publications: Wurbel el al (2006). Complex Regulation of CCR9 at Multiple Discrete Stages of T Cell Development. European Journal of Immunology 36, 73-81.

IPStatus: Not applicable